| Net sales | 21,156a | 20,993a |
| Cost of sales | -8,671a | -8,600a |
| Gross profit | 12,485a | 12,392a |
| Marketing and selling expenses | -4,536a | -4,510a |
| Administration expenses | -1,370a | -1,392a |
| Research and development costs | -2,279a | -2,445a |
| Impairment losses and reversals of impairment losses on financial assets (net) | -8a | -51a |
| Other operating income | 269a | 445a |
| Other operating expenses | -915a | -830a |
| Operating result (EBIT) | 3,645a | 3,609a |
| Finance income | 200a | 197a |
| Finance costs | -309a | -322a |
| Profit before income tax | 3,536a | 3,484a |
| Income tax | -751a | -650a |
| Profit after tax | 2,786a | 2,834a |
| Thereof: attributable to Merck KGaA shareholders (net income) | 2,777a | 2,824a |
| Thereof: attributable to non-controlling interests | 9a | 10a |